Previous literature on thyroid cancer survivors have shown that possible patient barriers to transitioning care included concerns related to side effects of thyroid hormone fluctuation, fear of disease recurrence, and a lack of confidence in PCPs to manage thyroid cancer follow-up, including unmet psychosocial needs [9,10,11,12]. This evidence concerns the gene TG and thyroid gland carcinoma.